Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer

The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinica...

Full description

Saved in:
Bibliographic Details
Published inMedeniyet medical journal Vol. 35; no. 2; pp. 99 - 105
Main Authors Demircan Tan, Berna, Turan, Turgay, Yucel, Burcu, Altundag Kara, Sedef, Salman Yilmaz, Seda, Yildirim, Asif
Format Journal Article
LanguageEnglish
Published Turkey Istanbul Medeniyet University 2020
Subjects
Original Study
DNA methylation
SOCS3
Prostate cancer
epigenetics
Online AccessGet full text

Cover

More Information
Summary:The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, blood-based epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa). A total of 41 consecutive patients and 10 healthy control groups were enrolled in the study. Pyrosequencing was performed to analyze the methylation levels of the promoter regions of the four tumor suppressor genes in patients compared to healthy controls. The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differ between the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localizedPCa (p<0.05). Our results indicated that SOCS3 could be a useful, noninvasive blood-based epigenetic biomarker for the diagnosis of locally advanced PCa.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Cite as: Demircan Tan B, Turan T, Yucel B, Altundag Kara S, Salman Yilmaz S, Yildirim A. Aberrant SOCS3 promoter methylation as a noninvasive diagnostic biomarker for locally advanced prostate cancer. Medeniyet Med J. 2020;35:99-105.
Ethics Committee Approval: This study was approved by the Istanbul Medeniyet University Goztepe Training and Research Hospital Ethic Committee for Clinical Studies (25 April 2018, 2018/0124).
Conflict of interest: The authors declare that they have no conflict of interest.
Funding: The Research Fund of Istanbul Medeniyet University supported this investigation (T-BAG-2016-678).
Informed Consent: Informed consent was taken from all participants.
ISSN:2149-2042
2149-4606
DOI:10.5222/MMJ.2020.58708